Fischesser Ryan 4
4 · Caribou Biosciences, Inc. · Filed Oct 7, 2022
Insider Transaction Report
Form 4
Fischesser Ryan
VP of Finance and Controller
Transactions
- Exercise/Conversion
Common Stock
2022-10-06$2.69/sh+2,839$7,637→ 113,205 total - Exercise/Conversion
Option to purchase Common Stock
2022-10-06−2,839→ 1,704 totalExercise: $2.69Exp: 2029-03-18→ Common Stock (2,839 underlying) - Exercise/Conversion
Option to purchase Common Stock
2022-10-06−2,839→ 15,337 totalExercise: $4.11Exp: 2031-03-29→ Common Stock (2,839 underlying) - Exercise/Conversion
Common Stock
2022-10-06$4.11/sh+2,839$11,668→ 116,044 total - Sale
Common Stock
2022-10-06$10.80/sh−10,000$107,958→ 110,366 total
Footnotes (4)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.67 to $10.94, inclusive. The reporting person undertakes to provide to Caribou Biosciences, Inc., any security holder of Caribou Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4.
- [F2]Includes 4,848 shares represented by restricted stock units ("RSUs") that vest in two equal annual installments beginning on August 22, 2023, subject to the reporting person's continued service to the Issuer through the applicable vesting dates.
- [F3]1/4th of the shares subject to this option vested on January 1, 2020 and an additional 1/48th of the aggregate number of shares subject to the option have vested or will vest on the corresponding day of each month thereafter until the option is fully vested on January 1, 2023, subject to the reporting person's continued service to the Issuer through the applicable vesting dates.
- [F4]1/4th of the shares subject to this option vested on January 1, 2022 and an additional 1/48th of the aggregate number of shares subject to the option have vested or will vest on the corresponding day of each month thereafter until the option is fully vested on January 1, 2025, subject to the reporting person's continued service to the Issuer through the applicable vesting dates.